Canopy Growth Corporation CGC PHARMA
Company Overview
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. The company operates through two segments, Cannabis and Storz & Bickel. It also provides vaporizers and accessories; dried flower and pre-rolled joints, oil, and vapes and beverages; extracts and concentrates, such as softgel capsules; and cannabis edibles, including gummies. In addition, the company operates e-commerce shop; medical cannabis online distribution platform; and an online medical cannabis clinic. It sells its products under the Tweed, 7ACRES, Deep Space, HiWay, Maitri, Twd., Spectrum Therapeutics, Canopy Medical, Abba Medix, Storz & Bickel, Wana, and Claybourne, Apollo, Canada House, R'belle, LowKey, MTL Cannabis, DeeLish, DOJA brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of $284.60M (+5.8% YoY); net profit $-262.91M.
- Trailing 12 Months Year-on-year growth — revenue +12.5%.
- 5-Year Trend Long-term compounding — revenue CAGR -5.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -5.12% |
| 1 Year: | 12.50% |
Stock Price Performance
| 1 Year: | -41.13% |
| 6 Months: | -9.77% |
| 3 Months: | -5.34% |
| 1 Month: | -0.46% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.85 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Revenue declined at -5.1% CAGR over 5 years.
- Trading 49.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CGC Canopy Growth Corporation PHARMA | 0.97 | -2.02 | $410.35M | 0.00% | -7.61% | -39.51% | -5.12% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 65.03M | 72.13M | 66.68M | 74.54M | 71.25M |
| Cost of Revenue | - | 54.49M | 54.10M | 44.78M | 53.08M | 62.98M |
| Gross Profit | - | 10.54M | 18.04M | 21.91M | 21.47M | 8.26M |
| Operating Expenses | - | 14.93M | 35.90M | 36.58M | 34.57M | 35.73M |
| Operating Income | - | -4.39M | -17.86M | -14.67M | -13.10M | -27.47M |
| EBITDA | - | -194.32M | -21.83M | 16.62M | -46.02M | -137.00M |
| Interest Expense | - | 15.38M | 9.74M | 8.80M | 7.34M | 12.31M |
| Pretax Income | - | -221.17M | -41.24M | -1.43M | -62.26M | -157.97M |
| Tax Provision | - | 329.00K | 291.00K | 214.00K | 368.00K | -850.00K |
| Net Income | - | -220.79M | -41.53M | -1.64M | -62.63M | -157.12M |
| Diluted EPS | - | -1.43 | -0.22 | -0.01 | -0.18 | -0.40 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 333.25M | 297.15M | 269.00M | 284.60M |
| Cost of Revenue | - | 396.78M | 216.26M | 189.48M | 214.93M |
| Gross Profit | - | -63.53M | 80.88M | 79.51M | 69.67M |
| Operating Expenses | - | 332.25M | 243.61M | 145.90M | 142.78M |
| Operating Income | - | -395.78M | -162.73M | -66.39M | -73.11M |
| EBITDA | - | -2.88B | -349.24M | -390.07M | -188.22M |
| Interest Expense | - | 126.16M | 105.35M | 74.57M | 38.19M |
| Pretax Income | - | -3.09B | -507.77M | -507.76M | -262.88M |
| Tax Provision | - | -5.73M | 12.33M | 7.14M | 23.00K |
| Net Income | - | -3.28B | -693.68M | -508.88M | -262.91M |
| Diluted EPS | - | -70.70 | -9.27 | -5.56 | -0.88 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 2.44B | 1.30B | 917.70M | 1.12B |
| Current Assets | - | 1.08B | 371.18M | 294.57M | 529.47M |
| Cash & Equivalents | - | 667.69M | 170.30M | 113.81M | 364.68M |
| Inventory | - | 83.23M | 77.29M | 96.37M | 110.51M |
| Receivables | - | 41.29M | 51.85M | 47.51M | 31.24M |
| Total Liabilities | - | 1.68B | 899.76M | 439.13M | 421.14M |
| Current Liabilities | - | 803.84M | 334.66M | 103.05M | 158.44M |
| Long Term Debt | - | 749.99M | 493.29M | 299.81M | 217.12M |
| Total Debt | - | 1.41B | 597.23M | 348.40M | 278.71M |
| Total Equity | - | 758.43M | 400.43M | 478.57M | 697.59M |
| Shares Outstanding | - | 51.73M | 91.12M | 183.87M | 422.07M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -557.55M | -281.95M | -165.75M | -63.81M |
| Investing Cash Flow | - | 433.38M | 241.59M | -47.79M | -21.35M |
| Financing Cash Flow | - | -19.69M | -465.06M | 148.66M | 332.41M |
| Capital Expenditure | - | -10.45M | -4.00M | -11.28M | -5.95M |
| Free Cash Flow | - | -568.00M | -285.95M | -177.03M | -69.76M |
| Net Change in Cash | - | -143.86M | -505.42M | -64.88M | 247.25M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | -19.1% | 27.2% | 29.6% | 24.5% |
| Operating Margin % | - | -118.8% | -54.8% | -24.7% | -25.7% |
| Net Margin % | - | -983.7% | -233.4% | -189.2% | -92.4% |
| ROE % | - | -432.2% | -173.2% | -106.3% | -37.7% |
| ROCE % | - | -24.2% | -16.9% | -8.1% | -7.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Tidal Investments LLC | 2.17% | 9.19M | $8.59M |
| 2 | Morgan Stanley | 0.46% | 1.95M | $1.82M |
| 3 | Lazard Asset Management LLC | 0.44% | 1.85M | $1.73M |
| 4 | Jane Street Group, LLC | 0.37% | 1.56M | $1.46M |
| 5 | UBS Group AG | 0.33% | 1.40M | $1.30M |
| 6 | Goldman Sachs Group Inc | 0.31% | 1.30M | $1.22M |
| 7 | Susquehanna International Group, LLP | 0.29% | 1.22M | $1.14M |
| 8 | Royal Bank of Canada | 0.26% | 1.08M | $1.01M |
| 9 | National Bank of Canada/FI/ | 0.20% | 858.46K | $802.14K |
| 10 | HRT Financial LP | 0.17% | 715.08K | $668.17K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CGC
Australia now has two new cannabis formats from Canopy Growth - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOTGR0WUh0cDJBOWZ6Qkc5bktvVzdVei1mYmhNUk1lZGhlaEtzNWdKUWNLems2cXpEbEpRY056Z3FneXpxRlRCemtTN2RFYkxQS09DeHItSUFJSmNDTUJ5M3ZQQjJidGZ1TjYyMk1RNDJZMmlnQW8tVlY1cENLdHZaSlVEUkRscGFZRXI0c3…
CGC Looks 39.2% Overvalued on GF Value™ - gurufocus.com
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxORzRlaGh2N2loV3E3STRqNHUwVGs5ODFtcVNIcWM0LTVEMDhwTUtrMGRMZS1OU2ZGYTJxWE1lMkFKajB1Q0tBT2tXNXZ5S2lyREZISlN2b2h2dVBEelRGSUtXZ0FEOFduQ1JlZEE2OGxraG5ZNlJQQkNhMUdwenpZTw?oc=5" target="_…
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPRmh2NzJaYzJCSFhMR1B2bFVmM0d1RFdtMC0xbktWQjBLNldpNUlPeXhsVVozRk5jRHNEa2Zlb0dhVU5OUVRpMlo2a1lLcENxekM0WmFjcjVrWWZrTHlHczFzRHYzYS1PeHNiSVlyeVo1cU5Gem5YOF9rUHRRODl0Skx5SG1YV0VxNHlGbi…
Can Canopy Growth (NASDAQ:CGC) Turn Revenue Growth Into a Real Turnaround? - Kalkine Media
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxOX0pJWkpjTEVCYXNsVE4wN0hjdkdZZzVSb3o1bkk0OG44dlJ3S1VIc29MWUc3NmIzeDVSdGMwdE1BUGtDQ1JHU0tQUnZXOU1qRm8tRURXcTBNM0NaelVPMkVTbWsxclY1enlRQVl1cG0yY0ZFWDhSUlJfUl9pSU1maXhYOGR0WV9mN0d2VW…
Should You Buy CGC Stock After Marijuana Reclassification? - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOOHFtbDhwaHNvakJ4UlFha3NUbmw0aDR1OVZvYmIzbjBqYko0X19ZQlhpZjJLUXdlT0ZfN0FuNUpjMDhOa0U2SVI3dkhoWjg0Zk9EcEk0al9OQXJLVmxIRVlDQ3MtTEVYX0ItMndPQ2ZsdnEtQVI2S3NnMHF1ZzlOYTQydHlaQjRSMGdQWG…
Should You Buy Canopy Growth Stock on the Rebound? - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPSXRjcGlwT1M4ZDh4RTFlTWxVY3V4UVh2MEJ0eDRyVnpGU1RqZ2dKYk5HbDNVSy1IWUVkZmZOWjZQZmE4T0UtbC1tWmxwVzZlcjZUR3BsU2k1RG1TT01HRXNUNnhJejJaTDB4NVhycUliMWtqZDlfc3J2NkRvOGxvMGJ2MWYxTXhQaXpaMk…
CGC — Frequently Asked Questions
What is the current share price of Canopy Growth Corporation (CGC)?
As of 2026-09-19 21:16 PDT, Canopy Growth Corporation (CGC) trades at $0.97 on NasdaqGS. Its 52-week range is $0.86 to $1.92.
What is the market capitalisation of CGC?
Canopy Growth Corporation (CGC) has a market capitalisation of $410.35M on NasdaqGS.
What is the P/E ratio of CGC?
CGC trades at a trailing price-to-earnings (P/E) ratio of -2.02. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.81.
What is the return on equity (ROE) of CGC?
CGC has a return on equity (ROE) of -39.51%. Its return on capital employed (ROCE) is -7.61%.
Is CGC a good stock to buy?
This page provides a data-driven analysis of Canopy Growth Corporation (CGC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.